Loading...
Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with few therapeutic targets and rare effective treatments. Over 90% of PDAC tumors bear a Kras mutation, and the single-site mutation G12D (Kras(G12D)) is most prevalent. Methods: Here, we applied the CRISPR-CasRx system...
Na minha lista:
| Udgivet i: | Theranostics |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ivyspring International Publisher
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7545986/ https://ncbi.nlm.nih.gov/pubmed/33052229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.46642 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|